Lessons in Hypertension from New Clinical Trials

References

• . World Health Organization. Fact sheet No. 317: cardiovascular diseases. February 2007. http://www.who.int/mediacentre/factsheets/fs317/en/print.html. Accessed February 22, 2009
   Google Scholar
• . Rosamond W, Flegal K, Furie K, ; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25–e146
   PubMed Web of Science ®Google Scholar
• . Dzau VJ, Antman EM, Black HR, . The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114(25):2850–2870
   Web of Science ®Google Scholar
• . Chobanian AV, Bakris GL, Black HR, ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252
   PubMed Web of Science ®Google Scholar
• . Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49(1):69–75
   PubMed Web of Science ®Google Scholar
• . Giles TD, Berk BC, Black HR, . Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich). 2005;7(9):505–512
   Google Scholar
• . ; ACCORD Study GroupBuse JB, Bigger JT, Byington RP, . Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99(12A):21i–33i
   Web of Science ®Google Scholar
• . Kalaitzidis R, Bakris GL. Lower blood pressure goals for cardiovascular and renal risk reduction: are they defensible? J Clin Hypertens (Greenwich). 2009;11(7):345–347
   Google Scholar
• . Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983–1992
   PubMed Web of Science ®Google Scholar
• . Mancia G, De Backer G, Dominiczak A, ; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–1187
   PubMed Web of Science ®Google Scholar
• . Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000;13(1 pt 2):3S–10S
   Google Scholar
• . Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;375(20):1571–1576
   Google Scholar
• . Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet. 2005;365(9457):434–441
   Google Scholar
• . Weycker D, Nichols GA, O'Keeffe-Rosetti M, . Risk-factor clustering and cardiovascular disease risk in hypertensive patients. Am J Hypertens. 2007;20(6):599–607
   Google Scholar
• . Mason RP. Nitric oxide mechanisms in the pathogenesis of global risk. J Clin Hypertens (Greenwich). 2006;8(8 suppl 2):31–38
   Google Scholar
• . Brunner H, Cockcroft JR, Deanfield J, ; Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23(2):233–246
   PubMed Web of Science ®Google Scholar
• . Rodriguez-Porcel M, Lerman LO, Herrmann J, Sawamura T, Napoli C, Lerman A. Hypercholesterolemia and hypertension have synergistic deleterious effects on coronary endothelial function. Arterioscler Thromb Vasc Biol. 2003;23(5):885–891
   Google Scholar
• . John S, Schmieder RE. Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. J Hypertens. 2000;18(4):363–374
   PubMed Web of Science ®Google Scholar
• . Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the healthy people 2010 blood pressure control goals. Hypertension. 2006;47(3):345–351
   PubMed Web of Science ®Google Scholar
• . Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358(9294):1682–1686
   PubMed Web of Science ®Google Scholar
• . Nesbitt SD, Julius S, Leonard D, Egan BM, Grozinski M; TROPHY Study Investigators. Is low-risk hypertension fact or fiction? Cardiovascular risk profile in the TROPHY Study. Am J Hypertens. 2005;18(7):980–985
   Google Scholar
• . Julius S, Nesbitt SD, Egan BM, ; Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354(16):1685–1697
   PubMedGoogle Scholar
• . Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet. 2007;370(9587):591–603
   PubMed Web of Science ®Google Scholar
• . Julius S, Nesbitt S, Egan B, ; TROPHY study group. Trial of preventing hypertension: design and 2-year progress report. Hypertension. 2004;44(2):146–151
   Google Scholar
• . Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913
   PubMed Web of Science ®Google Scholar
• . National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421
   PubMed Web of Science ®Google Scholar
• . Alberti KG, Zimmet PZ, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059–1062
   PubMed Web of Science ®Google Scholar
• . Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol. 2007;6:12
   PubMed Web of Science ®Google Scholar
• . Sowers JR, Haffner SM, Zappe DH, Condus C, Hsueh WA. Metabolic assessment of valsartan in comparison to thiazide therapy in pre-diabetic patients with the metabolic syndrome: the MADE-ITT Study. J Clin Hypertens (Greenwich). 2007;9(5 suppl A):A42. Abstract P-90 MP-39
   Google Scholar
• . Zappe DH, Sowers JR, Hsueh WA, . Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in pre-diabetic hypertensive patients with the cardiometabolic syndrome. J Clin Hypertens (Greenwich). 2008;10(12):894–903
   PubMed Web of Science ®Google Scholar
• . Dahlöf B, Devereux RB, Kjeldsen SE, ; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003
   PubMed Web of Science ®Google Scholar
• . Pfeffer MA, Swedberg K, Granger CB, ; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759–766
   PubMed Web of Science ®Google Scholar
• . Julius S, Kjeldsen SE, Weber M, ; for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022–2031
   PubMed Web of Science ®Google Scholar
• . Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol. 2007;99(7):1006–1012
   PubMed Web of Science ®Google Scholar
• . Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201–207
   PubMed Web of Science ®Google Scholar
• . ; DREAM Trial InvestigatorsBosch J, Yusuf S, Gerstein HC, . Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355(15):1551–1562
   PubMed Web of Science ®Google Scholar
• . ; ONTARGET InvestigatorsYusuf S, Teo KK, Pogue J, . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559
   PubMed Web of Science ®Google Scholar
• . ; The Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) InvestigatorsYusuf S, Teo K, Anderson C, Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174–1183
   Google Scholar
• . Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30–48
   PubMed Web of Science ®Google Scholar
• . Jamerson KA, Weber MA, Bakris GL, ; ACCOMPLISH investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–2428
   PubMed Web of Science ®Google Scholar
• . Dahlöf B, Sever PS, Poulter NR, ; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906
   PubMed Web of Science ®Google Scholar
• . Califf RM, Boolell M, Haffner SM, ; NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J. 2008;156(4):623–632
   PubMed Web of Science ®Google Scholar
• . Schmieder RE. Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum? J Hypertens. 2006;24( suppl 2):S31–S35
   Google Scholar
• . Brenner BM, Cooper ME, de Zeeuw D, ; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869
   PubMed Web of Science ®Google Scholar
• . Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878
   PubMed Web of Science ®Google Scholar
• . Lewis EJ, Hunsicker LG, Clarke WR, ; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860
   PubMed Web of Science ®Google Scholar
• . Viberti G, Wheeldon NM; for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106(6):672–678
   Google Scholar
• . Makino H, Haneda M, Babazono T, ; INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1577–1578
   PubMed Web of Science ®Google Scholar
• . Hollenberg NK, Parving HH, Viberti G, . Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25(9):1921–1926
   PubMed Web of Science ®Google Scholar
• . Haller H, Viberti GC, Mimran A, ; Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens. 2006;24(2):403–408
   PubMed Web of Science ®Google Scholar
• . Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes mellitus and nephropathy. N Engl J Med. 2008;358:2433–2446
   PubMed Web of Science ®Google Scholar
• . Solomon SD, Appelbaum E, Manning WJ, ; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119(4):530–537
   PubMed Web of Science ®Google Scholar
• . Parving HH, Brenner BM, McMurray JJ, . Aliskiren Trial in Type 2 Diabetes Mellitus Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009;24(5):1663–1671
   PubMed Web of Science ®Google Scholar
• . Nissen SE, Tuzcu EM, Libby P, ; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217–2226
   PubMed Web of Science ®Google Scholar
• . European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of hypertension. J Hypertens. 2003;21(6):1011–1053
   PubMed Web of Science ®Google Scholar
• . Douglas JG, Bakris GL, Epstein M, ; Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society of Hypertension in Blacks. Arch Intern Med. 2003;163(5):525–541
   PubMedGoogle Scholar
• . Smith SC Jr, Allen J, Blair SN, ; AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation. 2006;113(19):2363–2372
   PubMed Web of Science ®Google Scholar
• . Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation. 2006;113(25):2943–2946
   PubMed Web of Science ®Google Scholar
• . Mosca L, Banka CL, Benjamin EJ, ; Expert Panel/Writing Group; American Heart Association; American Academy of Family Physicians, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115(11):1481–1501
   PubMedGoogle Scholar
• . Rosendorff C, Black HR, Cannon CP, ; American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115(21):2761–2788
   PubMed Web of Science ®Google Scholar
• . Giles TD. Assessment of global risk: a foundation for a new, better definition of hypertension. J Clin Hypertens (Greenwich). 2006;8(8 suppl 2):5–14
   Google Scholar
• . National Institutes of Health. Cardiovascular disease risk reduction, adults/cholesterol guidelines update, ATP IV/hypertension guidelines update, JNC 8/obesity guidelines update, adults: background. http://www.nhlbi.nih.gov/guidelines/cvd_adult/background.htm. Accessed February 22, 2009
   Google Scholar